| Company Name: | Amylin Pharmaceuticals Inc | | Ticker Symbol: | AMLN | | | WWW Address: | www.amylin.com |
| CEO: | Daniel M. Bradbury | | No. of Employees: | 1,300 |
| Common Issue Type: | CS | | Business Description: | Amylin Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of innovative medicines for the treatment of diabetes, obesity and other diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 30.98 |  0.0 | - | - | | 31.02 | 30.98 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 5,089.5 | 164.3 | 1.66 | -3.73 | 0.00 | 0.0 | 0.0 | 31.02 - 8.03 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 30.98 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 5,089.5 | mil |
| Latest Shares Outstanding | 164.3 | mil |
| Earnings pS (EPS) | -3.73 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 500,522 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 118.5 | mil |
| Float as % of Shares Outstanding | 73.3 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 69.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 25.30 | % |
| Gross Profit Margin | 94.6 | % |
| EBITDA Margin | -0.4 | % |
| Pre-Tax Profit Margin | -97.7 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | -32.4 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -39.4 | % |
| Current Ratio | 1.9 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 103.0 | % |
| Working Capital pS | 1.60 | $ |
| Cash pS | 0.58 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -1.83 | $ |
| Cash Flow pS | -3.49 | $ |
| Free Cash Flow pS | -0.52 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -16.93 | |
| Price/Cash Flow | -8.9 | |
| Price/Free Cash Flow | -59.2 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.1 | 99 | 34,611 | 128,637 |
| 4 Weeks | 31.02 | 30.75 | 30.79 | 0.6 | 97 | 33,582 | 604,469 |
| 13 Weeks | 31.02 | 24.97 | 25.86 | 19.8 | 116 | 59,365 | 3,621,282 |
| 26 Weeks | 31.02 | 15.18 | 17.17 | 80.4 | 173 | 50,002 | 6,200,236 |
| 52 Weeks | 31.02 | 8.03 | 10.11 | 206.4 | 258 | 37,739 | 9,397,030 |
| YTD | 31.02 | 10.68 | - | 172.2 | 244 | 50,110 | 7,616,765 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 30.97 | 30.90 | 29.44 | 23.27 | 19.71 | 1.66 | 1.35 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -3.26 | 38.9 | -5.99 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -17.76 | NA | -42.77 |
| R&D | -10.17 | NA | -10.95 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 3.9 | 7.1 | -2.7 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.64 | -0.24 | -2.67 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 6.69 |
| Current Ratio | 1.4 |
| Quick Ratio (Acid Test) | 0.8 |
| Liquidity Ratio (Cash) | 0.72 |
| Receivables Turnover | 13.0 |
| Average Collection Period | 28 |
| Working Capital/Equity | -90.2 |
| Working Capital pS | 0.86 |
| Cash-Flow pS | -3.38 |
| Free Cash-Flow pS | 0.23 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 0.54 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 107.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 112.5 |
| LT Debt/Total Liabilities | 82.7 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 3.30 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 81.20 |
| Tobin's Q Ratio | 2.72 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -130.67 |
| Enterprise Value (EV)/Free Cash Flow | 163.25 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -16.93 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -8.9 |
| Price/Free Cash Flow Ratio - LTM | -59.2 |
| Price/Sales Ratio | 7.68 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 11.36 |
| Current Liabilities pS | 2.02 |
| Tangible Book Value pS - LTM | -1.83 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 9.27 |
| Cash pS - LTM | 0.58 |
| Cash Flow pS - LTM | -3.49 |
| Free Cash Flow pS - LTM | -0.52 |
| Earnings pS (EPS) | -3.73 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 5.20 |
| Free Cash Flow Margin 5YEAR AVG | -23.90 |
| Net Profit Margin | -83.5 |
| Net Profit Margin - 5YEAR AVRG. | -38.1 |
| Equity Productivity | -4.69 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.43 |
| Return on Capital Invested (ROCI) | -35.7 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -23.0 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | -29.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | -16.3 |
| Gross Profit Margin | 94.6 |
| Gross Profit Margin - 5YEAR AVRG. | 95.0 |
| EBITDA Margin - LTM | -0.4 |
| EBIT Margin - LTM | -78.9 |
| Pre-Tax Profit Margin | -91.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -39.4 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 883 |
| Revenue per Employee | 500,522 |
| Net Income per Employee | -417,999 |
| Average Collection Period | 25 |
| Receivables Turnover | 13.0 |
| Day's Inventory Turnover Ratio | 858 |
| Inventory Turnover | 0.4 |
| Inventory/Sales | 17.2 |
| Accounts Payble/Sales | 17.48 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | 5.20 |
| Fixed Assets Turnover | 0.45 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 6.52 |
| Revenue per $ Plant | 0.78 |
| Revenue per $ Common Equity | -4.69 |
| Revenue per $ Capital Invested | 0.43 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 75.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 51.7 |
| Research & Devlopment (R&D) as % of Revenue | 24.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 24.8 |
|
|  
| | |  |  | |
| |
